Phase I clinical trials for new drugs using fMRI provides an opportunity to define efficacy, potential side effects, and comparative effects with the current standard (if available) in a small cohort of individuals. Our Phase I program is conducted at the MGH and has the following basic facilities.

• Recruiting
• Critical Care Team monitoring in MRI scanner
• Established methods for phMRI including PK and PD
• Research Pharmacy
• Prior experience in working in and with Industry
  • Industry Sponsored Trials
  • Rapid turnaround with MGH Office of Tech Transfer
  • FDA Regulatory Requirements
• GCRC facilities available at Hospital and Imaging Site
• Novel Methodologies developed for fMRI Drug Evaluation
• FDA Experience

relevant p.a.i.n. group publications